Page 29 - Platform Technology News Today

The Nio share price has underperformed some of the hardest hit tech stocks, despite steering clear of Beijing’s competition probes. Read our full analysis.

Freeline Appoints Michael J. Parini as Chief Executive Officer and Reports Second Quarter 2021 Financial Results On track for three programs in the clinic by year end; trial... | August 17, 2021

Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline Synaffix will provide all necessary proprietary ADC technologies, including GlycoConnect, HydraSpace, and select toxSYN linker-payloads Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with optimized therapeutic index Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, "Kyowa Kirin"), a global specialty pharmaceutical company that strives to create new va...

PRESS RELEASE iosBio appoints Patricia Londono-Hayes as Chief Development Officer Oral vaccines and biotherapeutics company strengthens senior leadership team with new role to drive priority development programmes Burgess Hill, UK, 14 June 2021—iosBio (‘the Company’), a UK-based biotechnology company developing next-generation vaccines that can be administered orally, today announces the appointment of Patricia Londono-Hayes, PhD, as Chief Development Officer. With more than...

Travecta Therapeutics, Pte Ltd. incorporated in Singapore on 7th April 2017, a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment of Charles S. Ryan, JD, PhD as President and Chief Executive Officer. Dr. Ryan recently served as Chief Executive Officer and Director of Neurotrope, Inc. In his new role, Dr. Charles Ryan will work closely with the scientific team to develop novel therap

Katalin Karikó said that mRNA technology is extremely adaptable. It could be used to cure afflications such as influenza, HIV, and perhaps even cancer.

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results Licensing Partners Leveraging PolyXen® Platform Technology Continue To Make Clinical, Regulatory and Commercial Advancement FRAMINGHAM, MA / ACCESSWIRE / May 12, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial...

Share this article Share this article ResearchAndMarkets.coms offering. The number of people being vaccinated with influenza vaccines worldwide will reach 500 million by the year-end of 2027. The Report Analyses the Market Based on Countries and Presents the Forecast in Terms of Value and Volume for the Next Six Years. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza va...

Wednesday, May 5, 2021 9:18 AM Tweet We are looking for a Front-end Web Developer to join our Platform Technology unit. You are motivated to combine the art of design with the art of software development. As a front-end web developer, you will ensure the best possible performance, quality, and responsiveness of the application. You’ll be part of a cross-functional team that is responsible for the full software development life cycle, from conception to deployment. Responsibilities: Cooperate ...

Battery storage: the next oil – and gas? [GasTransitions] Apr 14, 2021 7:15:am Summary The race for battery storage capacity is on. In countries like Australia and the US, an increasing number of ever-larger battery grid storage projects are being announced. [Gas Transitions Volume 2, Issue 3] by: Karel Beckman The race for battery storage capacity is on. In countries like Australia and the US, an increasing number of ever-larger battery grid storage projects are b...